Essex Bio-Technology (SEHK:1061) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

1061 Panoramica delle azioni

Essex Bio-Technology Limited, una holding di investimento, sviluppa, produce, distribuisce e vende prodotti biofarmaceutici nella Repubblica Popolare Cinese, a Hong Kong e a livello internazionale.

Informazioni sull'azienda

1061 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	4/6
Salute finanziaria	6/6
Dividendi	4/6

Premi

Il rapporto prezzo/utile ( 5 x) è inferiore al mercato Hong Kong ( 9 x)

Gli utili sono cresciuti del 22.1% nell'ultimo anno

Analisi del rischio

Andamento instabile dei dividendi

Essex Bio-Technology Limited Concorrenti

TOT BIOPHARM International

SEHK:1875

HK$1.4b

Uni-Bio Science Group

SEHK:690

HK$326.7m

HBM Holdings

SEHK:2142

HK$813.3m

3SBio

SEHK:1530

HK$13.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Essex Bio-Technology
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$2.37
Massimo di 52 settimane	HK$3.20
Minimo di 52 settimane	HK$1.96
Beta	0.25
1Variazione di 1 mese	0.85%
Variazione a 3 mesi	-5.58%
Variazione di 1 anno	-25.00%
3Variazione a 3 anni	-62.97%
Variazione a 5 anni	-52.02%
Variazione dall'IPO	139.39%

Notizie e aggiornamenti recenti

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Rendimenti per gli azionisti

	1061	HK Biotechs	HK Mercato
7D	-1.3%	-0.6%	0.3%
1Y	-25.0%	-26.5%	4.0%

Ritorno vs Industria: 1061 ha superato il Hong Kong Biotechs che ha restituito -26.5 % nell'ultimo anno.

Rendimento vs Mercato: 1061 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 3.3 % nell'ultimo anno.

Volatilità dei prezzi

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement	4.0%
Biotechs Industry Average Movement	7.3%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.1%
10% least volatile stocks in HK Market	3.3%

Prezzo delle azioni stabile: 1061 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di 1061 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1990	1,481	Haizhou Fang	www.essexbio.com

Essex Bio-Technology Limited, una holding di investimento, sviluppa, produce, distribuisce e vende prodotti biofarmaceutici nella Repubblica Popolare Cinese, a Hong Kong e a livello internazionale. L'azienda opera attraverso i segmenti Oftalmologia e Chirurgia. L'azienda ricerca e sviluppa prodotti terapeutici a base di fattore di crescita dei fibroblasti per il trattamento della proliferazione, differenziazione e migrazione cellulare.

Essex Bio-Technology Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Essex Bio-Technology con la sua capitalizzazione di mercato?
1061 statistiche fondamentali
Capitalizzazione di mercato	HK$1.35b
Guadagni(TTM)	HK$275.26m
Ricavi(TTM)	HK$1.71b

4.9x

Rapporto P/E

0.8x

Rapporto P/S

1061 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
1061 Conto economico (TTM)
Ricavi	HK$1.71b
Costo del fatturato	HK$167.26m
Profitto lordo	HK$1.54b
Altre spese	HK$1.26b
Guadagni	HK$275.26m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

Aug 26, 2024

Utile per azione (EPS)	0.49
Margine lordo	90.20%
Margine di profitto netto	16.13%
Rapporto debito/patrimonio netto	14.1%

Come si è comportato 1061 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.8%

Rendimento attuale del dividendo

19%

Rapporto di remunerazione

1061 Panoramica delle azioni

Premi

Analisi del rischio

Essex Bio-Technology Limited Concorrenti

SEHK:1875

HK$1.4b

SEHK:690

HK$326.7m

SEHK:2142

HK$813.3m

SEHK:1530

HK$13.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Recent updates

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?